Evidence map›Paper›PMID 20634346›Full record

SynthesisBMJ (Clinical research ed.)2010

Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.

Patrick F van Rheenen, Els Van de Vijver, Vaclav Fidler

2 registry-linked trialsOpen access · hybridAbstract readEvaluation StudyMeta-AnalysisReview
In one paragraph

Synthesis in BMJ (Clinical research ed.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 260 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
260citing papers in PubMed, 9 pooled it
32.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02351635 completednot on this mapstarted 2015, after this paper: background citation

Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome

TypeobservationalSponsorBühlmann Laboratories AGRan2015 to 2018Enrolled478ConditionsInflammatory Bowel Disease, Irritable Bowel SyndromeArmsfecal calprotectin level
NCT04491799 completednot on this mapstarted 2019, after this paper: background citation

Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea

TypeobservationalSponsorMahidol UniversityRan2019 to 2020Enrolled135ConditionsDiarrhea, CalprotectinArmsFecal calprotectin
3 · Its place in the literature

Who cites it

260 citing papers in PubMed, 9 syntheses or guidelines pooled it, 708 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin vs. Fecal Immunochemical Test: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Effect of PostbioticNutrients · 2024
    Trial
  11. LIAISONUnited European gastroenterology journal · 2022
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Article
  20. Article

200 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Patrick F van RheenenBeatrix Children's Hospital, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, Netherlands. p.f.van.rheenen@bkk.umcg.nl
Els Van de Vijver
Vaclav Fidler
University Medical Center Groningen · NLBeatrix Kinderziekenhuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate whether including a test for faecal calprotectin, a sensitive marker of intestinal inflammation, in the investigation of suspected inflammatory bowel disease reduces the number of unnecessary endoscopic procedures.

designMeta-analysis of diagnostic accuracy studies. DATA SOURCES: Studies published in Medline and Embase up to October 2009. Interventions reviewed Measurement of faecal calprotectin level (index test) compared with endoscopy and histopathology of segmental biopsy samples (reference standard). Inclusion criteria Studies that had collected data prospectively in patients with suspected inflammatory bowel disease and allowed for construction of a two by two table. For each study, sensitivity and specificity of faecal calprotectin were analysed as bivariate data to account for a possible negative correlation within studies.

results13 studies were included: six in adults (n=670), seven in children and teenagers (n=371). Inflammatory bowel disease was confirmed by endoscopy in 32% (n=215) of the adults and 61% (n=226) of the children and teenagers. In the studies of adults, the pooled sensitivity and pooled specificity of calprotectin was 0.93 (95% confidence interval 0.85 to 0.97) and 0.96 (0.79 to 0.99) and in the studies of children and teenagers was 0.92 (0.84 to 0.96) and 0.76 (0.62 to 0.86). The lower specificity in the studies of children and teenagers was significantly different from that in the studies of adults (P=0.048). Screening by measuring faecal calprotectin levels would result in a 67% reduction in the number of adults requiring endoscopy. Three of 33 adults who undergo endoscopy will not have inflammatory bowel disease but may have a different condition for which endoscopy is inevitable. The downside of this screening strategy is delayed diagnosis in 6% of adults because of a false negative test result. In the population of children and teenagers, 65 instead of 100 would undergo endoscopy. Nine of them will not have inflammatory bowel disease, and diagnosis will be delayed in 8% of the affected children.

conclusionTesting for faecal calprotectin is a useful screening tool for identifying patients who are most likely to need endoscopy for suspected inflammatory bowel disease. The discriminative power to safely exclude inflammatory bowel disease was significantly better in studies of adults than in studies of children.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkersChildEndoscopy, GastrointestinalFecesHumansInflammatory Bowel DiseasesLeukocyte L1 Antigen ComplexMiddle AgedReference StandardsUnnecessary ProceduresYoung AdultBiomarkersLeukocyte L1 Antigen Complex

Identifiers

PMID20634346
PMCPMC2904879
OpenAlexW2077129981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.